Zealand Pharma A/S (OTCMKTS:ZLDPF) Announces Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.19, Zacks reports. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $28.11 million.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF remained flat at $108.30 during mid-day trading on Friday. 240 shares of the stock traded hands, compared to its average volume of 307. The company has a 50 day moving average of $101.97 and a two-hundred day moving average of $113.60. The firm has a market capitalization of $7.69 billion, a P/E ratio of -45.89 and a beta of 0.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. Zealand Pharma A/S has a 12 month low of $67.58 and a 12 month high of $141.74.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st. JPMorgan Chase & Co. started coverage on shares of Zealand Pharma A/S in a report on Friday, November 8th. They set an "overweight" rating for the company.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.